Our Data

An ever-growing body of data

We partner with academic institutions to evaluate our ex vivo platform. These efforts include research collaborations and ongoing clinical trials. Here, we invite you to dive deeper into the data behind our platform.

Our publications

Paper published in Journal of Biomedical Optics

Label-free fluorescence lifetime imaging for the assessment of cell viability in living tumor fragments

We have developed and fully characterized a label-free imaging assay of cell viability based on multiphoton fluorescence lifetime imaging microscopy that leaves tissues intact and viable for repeated assessment of specimens over time, as well as downstream evaluation with other Elephas platform assays.

See publication

Paper published in Biomedical Optics Express

Assessing cell viability with dynamic optical coherence microscopy

We demonstrate that dynamic optical coherence microscopy, a technical component of the Elephas platform, can distinguish live cells from dead cells in murine syngeneic tumors.

See publication

Poster presented at AACR 2024, San Diego

Assessing cytotoxic T cell responses to immune checkpoint inhibitors in murine and human tumor samples using metabolic imaging

The Elephas platform can be used to assess immune checkpoint inhibitor response in clinically relevant core needle biopsies.

See poster

Poster presented at SITC 2023, San Diego

Assessing cytotoxic T cell responses in live tumor fragments with multiphoton microscopy

The Elephas platform can simultaneously assess activation of T cells and cytotoxic killing of tumor cells in response to immune checkpoint inhibitors.

See poster

Poster presented at AACR 2023, Orlando

Label-free imaging for rapid assessment of tumor viability in live tumor fragments

Using nondestructive, label-free multiphoton microscopy, the Elephas platform accurately predicts live/dead status of live tumor fragments (LTFs) and can assess tumors longitudinally.

See poster

Poster presented at SITC 2022, Boston

Murine live tumor fragments can be used to assess immunotherapy response

The Elephas platform addresses heterogeneity of tumors and creates homogenous treatment groups which can receive adoptive T cells, indicating CAR T-cell therapy can be assessed on the platform.

See poster

Poster presented at AACR 2022, New Orleans

A live tumor fragment platform with imaging for immune response assays

LTFs are viable, maintain motility of T cells and respond to checkpoint inhibitors by increasing cell surface marker expression and cytokine production, supporting the maintenance of the tumor microenvironment in our platform.

See poster

Poster presented at AACR 2022, New Orleans

Tumor/normal and live/dead classification in live tumor fragments using label-free multiphoton microscopy

The Elephas platform leverages nondestructive multiphoton label-free imaging to differentiate between live and dead cells in LTFs.

See poster

Poster presented at AACR 2022, New Orleans

Dynamic imaging of T cell surveillance in live tumor fragments using camelid nanobodies

The Elephas platform can track the motility of T cells and can distinguish T cells from tumor associated macrophages.

See poster

OUR CLINICAL TRIALS

Elephas is conducting three observational clinical trials. The primary objective of these studies is to determine the ex-vivo predictive accuracy of the Elephas platform across a variety of solid tumors.

Study endpoints:

  • Sensitivity and specificity of Elephas platform for predicting clinical response to immune checkpoint inhibitors
  • Compare to existing FDA approved biomarkers
  • Compare clinical benefit of predicted responders (PD-L1, MSI, MMR and TMB) and non-responders (ORR, DCR, PFS, OS)

Measured per RECIST v1.1 and iRECIST

Primary endpoint: Sensitivity in predicting clinical response to immunotherapy

CYBRID-01: Lung Trial

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

ele-changing-the-view

Tumor types:

Non-small cell lung cancer

Setting:

Metastatic & recurrent

Complete study details: NCT05478538

CYBRID-02: Basket Trial in Collaboration with Hoosier Cancer Research Network

Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

ele-changing-the-view

Tumor types:

Bladder cancerColorectal cancerEndometrial cancerHead & neck cancerKidney cancerLiver cancerMelanomaNon-small cell lung cancerTriple negative breast cancer

Setting:

Metastatic & recurrentAdvanced

Complete study details: NCT05520099

ELEPHAS-04: Mayo Clinic

Mayo Clinic MC230901: Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

mayo-clinic-logo-grey

Tumor types:

Bladder cancerColorectal cancerEndometrial cancerHead & neck cancerKidney cancerLiver cancerMelanomaNon-small cell lung cancerTriple negative breast cancer

Setting:

Metastatic & recurrentAdvancedNeoadjuvantAdjuvant

Complete study details: NCT0634962

These trials will provide an opportunity to demonstrate correlation between ex vivo and clinical response to immunotherapy regimenS.

Clinical Trial Design

ele-data-clinicaltrialworkflow-01 ele-data-clinicaltrialworkflow-02

We are enrolling over 600 patients in our studies.

Hospitals and academic research centers within the US provide consented patient specimens.

If you are a physician or researcher, contact us to learn more.

Contact us